1
|
Structural dynamics of the cooperative binding of small inhibitors in human cytochrome P450 2C9. J Mol Graph Model 2022; 113:108151. [DOI: 10.1016/j.jmgm.2022.108151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 02/03/2022] [Accepted: 02/03/2022] [Indexed: 11/23/2022]
|
2
|
Abstract
A variety of environmental toxicants such as heavy metals, pesticides, organic
chemicals, etc produce harmful effects in our living systems. In the literature, various reports have
indicated the detrimental effects of toxicants such as immunotoxicity, cardiotoxicity,
nephrotoxicity, etc. Experimental animals are generally used to investigate the safety profile of
environmental chemicals, but research on animals has some limitations. Thus, there is a need for
alternative approaches. Docking study is one of the alternate techniques which predict the binding
affinity of molecules in the active site of a particular receptor without using animals. These
techniques can also be used to check the interactions of environmental toxicants towards biological
targets. Varieties of user-friendly software are available in the market for molecular docking, but
very few toxicologists use these techniques in the field of toxicology. To increase the use of these
techniques in the field of toxicology, understanding of basic concepts of these techniques is
required among toxicological scientists. This article has summarized the fundamental concepts of
docking in the context of its role in toxicology. Furthermore, these promising techniques are also
discussed in this study.
Collapse
Affiliation(s)
- Meenakshi Gupta
- Department of Pharmacology, Indo-Soviet Friendship Pharmacy College (ISFCP), Moga, Punjab, India
| | - Ruchika Sharma
- Department of Biotechnology, Indo-Soviet Friendship College of Professional Studies (ISFCPS), Moga, Punjab, India
| | - Anoop Kumar
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Raebareli, Lucknow (UP), India
| |
Collapse
|
3
|
Discovery and structure-activity relationship of auriculatone: A potent hepatoprotective agent against acetaminophen-induced liver injury. Bioorg Med Chem Lett 2017; 27:3636-3642. [DOI: 10.1016/j.bmcl.2017.07.028] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2017] [Revised: 06/16/2017] [Accepted: 07/08/2017] [Indexed: 02/05/2023]
|
4
|
Zak M, Yuen PW, Liu X, Patel S, Sampath D, Oeh J, Liederer BM, Wang W, O’Brien T, Xiao Y, Skelton N, Hua R, Sodhi J, Wang Y, Zhang L, Zhao G, Zheng X, Ho YC, Bair KW, Dragovich PS. Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. J Med Chem 2016; 59:8345-68. [DOI: 10.1021/acs.jmedchem.6b00697] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Mark Zak
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Po-wai Yuen
- Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Xiongcai Liu
- Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Snahel Patel
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Deepak Sampath
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Jason Oeh
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Bianca M. Liederer
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Weiru Wang
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Thomas O’Brien
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Yang Xiao
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Nicholas Skelton
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Rongbao Hua
- Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Jasleen Sodhi
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Yunli Wang
- Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Lei Zhang
- Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Guiling Zhao
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Xiaozhang Zheng
- FORMA Therapeutics Inc., 500 Arsenal Street, Watertown, Massachusetts 02472, United States
| | - Yen-Ching Ho
- FORMA Therapeutics Inc., 500 Arsenal Street, Watertown, Massachusetts 02472, United States
| | - Kenneth W. Bair
- FORMA Therapeutics Inc., 500 Arsenal Street, Watertown, Massachusetts 02472, United States
| | - Peter S. Dragovich
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
5
|
Nair PC, McKinnon RA, Miners JO. Cytochrome P450 structure–function: insights from molecular dynamics simulations. Drug Metab Rev 2016; 48:434-52. [DOI: 10.1080/03602532.2016.1178771] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
6
|
Li Z, Li Y, Sun L, Tang Y, Liu L, Zhu W. Artificial neural network cascade identifies multi-P450 inhibitors in natural compounds. PeerJ 2015; 3:e1524. [PMID: 26719820 PMCID: PMC4696407 DOI: 10.7717/peerj.1524] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2015] [Accepted: 11/30/2015] [Indexed: 12/27/2022] Open
Abstract
Substantial evidence has shown that most exogenous substances are metabolized by multiple
cytochrome P450 (P450) enzymes instead of by merely one P450 isoform. Thus, multi-P450
inhibition leads to greater drug-drug interaction risk than specific P450 inhibition.
Herein, we innovatively established an artificial neural network cascade (NNC) model
composed of 23 cascaded networks in a ladder-like framework to identify potential
multi-P450 inhibitors among natural compounds by integrating 12 molecular descriptors into
a P450 inhibition score (PIS). Experimental data reporting in vitro
inhibition of five P450 isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) were
obtained for 8,148 compounds from the Cytochrome P450 Inhibitors Database (CPID). The
results indicate significant positive correlation between the PIS values and the number of
inhibited P450 isoforms (Spearman’s ρ = 0.684, p <
0.0001). Thus, a higher PIS indicates a greater possibility for a chemical to inhibit the
enzyme activity of at least three P450 isoforms. Ten-fold cross-validation of the NNC
model suggested an accuracy of 78.7% for identifying whether a compound is a multi-P450
inhibitor or not. Using our NNC model, 22.2% of the approximately 160,000 natural
compounds in TCM Database@Taiwan were identified as potential multi-P450 inhibitors.
Furthermore, chemical similarity calculations suggested that the prevailing parent
structures of natural multi-P450 inhibitors were alkaloids. Our findings show that
dissection of chemical structure contributes to confident identification of natural
multi-P450 inhibitors and provides a feasible method for virtually evaluating multi-P450
inhibition risk for a known structure.
Collapse
Affiliation(s)
- Zhangming Li
- Department of Pharmacy Administration, Harbin Medical University , Harbin , China
| | - Yan Li
- Department of Pharmacy, The Fourth Hospital of Harbin Medical University , Harbin , China
| | - Lu Sun
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology , Shanghai , China
| | - Yun Tang
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology , Shanghai , China
| | - Lanru Liu
- Department of Pharmacy Administration, Harbin Medical University , Harbin , China
| | - Wenliang Zhu
- Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University , Harbin , China
| |
Collapse
|
7
|
Brunner-Ziegler S, Jilma B, Magirr D, Sunder-Plassmann R, Giurgea GA, Hammer A, Margeta C, Brunner M, Koppensteiner R, Mannhalter C. Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study. Br J Haematol 2014; 167:547-53. [PMID: 25142093 DOI: 10.1111/bjh.13082] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Accepted: 07/09/2014] [Indexed: 12/30/2022]
Abstract
Interindividual variations in dose requirements of oral vitamin K antagonists (VKA) are attributed to several factors, including genetic variant alleles of vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9), but also interaction with co-medications. In this context, proton pump inhibitor (PPI)-related alterations of VKA maintenance dose requirements have been published. The present investigation aimed to test for an interaction profile of oral VKA-therapy and PPIs in relation to the CYP2C9 genotype. Median weekly stable VKA dose requirements over 1 year were recorded in 69 patients. Patients were genotyped for CYP2C9*2, CYP2C9*3, VKORC1c.-1639G>A and VKORC1c.174-136C>T and assessed for an association with PPI use and total VKA maintenance dose requirements. PPI users with CYP2C9 genetic variations required significantly lower weekly VKA maintenance doses than those with the wild-type genotype (t-test: P = 0·02). In contrast, in subjects without PPI use, the CYP2C9 genotype had no significant influence on oral VKA dose requirements. Further, the combined CYP2C9/VKORC1 genotype was a significant predictor for VKA dose requirements [linear regression: estimate: -1·47, standard error: 0·58 (P = 0·01)]. In conclusion, in carriers of CYP2C9 gene variations, the interference with the VKA metabolism is modified by PPI co-medication and the VCKORC1 genotype. Preceding knowledge of the genetic profile and the awareness for potentially occurring severe over-anticoagulation problems under PPI co-medication could contribute to a safer and personalized VKA pharmacotherapy.
Collapse
Affiliation(s)
- Sophie Brunner-Ziegler
- Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Estrada DF, Skinner AL, Laurence JS, Scott EE. Human cytochrome P450 17A1 conformational selection: modulation by ligand and cytochrome b5. J Biol Chem 2014; 289:14310-20. [PMID: 24671419 DOI: 10.1074/jbc.m114.560144] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Crystallographic studies of different membrane cytochrome P450 enzymes have provided examples of distinct structural conformations, suggesting protein flexibility. It has been speculated that conformational selection is an integral component of substrate recognition and access, but direct evidence of such substate interconversion has thus far remained elusive. In the current study, solution NMR revealed multiple and exchanging backbone conformations for certain structural features of the human steroidogenic cytochrome P450 17A1 (CYP17A1). This bifunctional enzyme is responsible for pregnenolone C17 hydroxylation, followed by a 17,20-lyase reaction to produce dehydroepiandrosterone, the key intermediate in human synthesis of androgen and estrogen sex steroids. The distribution of CYP17A1 conformational states was influenced by temperature, binding of these two substrates, and binding of the soluble domain of cytochrome b5 (b5). Notably, titration of b5 to CYP17A1·pregnenolone induced a set of conformational states closely resembling those of CYP17A1·17α-hydroxypregnenolone without b5, providing structural evidence consistent with the reported ability of b5 to selectively enhance 17,20-lyase activity. Solution NMR thus revealed a set of conformations likely to modulate human steroidogenesis by CYP17A1, demonstrating that this approach has the potential to make similar contributions to understanding the functions of other membrane P450 enzymes involved in drug metabolism and disease states.
Collapse
Affiliation(s)
- D Fernando Estrada
- From the Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66045 and
| | - Andria L Skinner
- From the Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66045 and
| | - Jennifer S Laurence
- the Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047
| | - Emily E Scott
- From the Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66045 and
| |
Collapse
|
9
|
Brändén G, Sjögren T, Schnecke V, Xue Y. Structure-based ligand design to overcome CYP inhibition in drug discovery projects. Drug Discov Today 2014; 19:905-11. [PMID: 24642031 DOI: 10.1016/j.drudis.2014.03.012] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Revised: 02/26/2014] [Accepted: 03/11/2014] [Indexed: 01/01/2023]
Abstract
Cytochrome P450 (CYP) enzymes are key players in xenobiotic metabolism, and inhibition of CYPs can therefore result in unwanted drug-drug interactions. Within drug discovery, CYP inhibition can cause delays in the progression of candidate drugs, or even premature closure of projects. During the past decade, a massive effort in the pharmaceutical industry and academic research has produced a wealth of structural information in the CYP field. In this short review, we will describe how structure-based approaches can be used in the pharmaceutical industry to work away from CYP inhibition, with a focus on the opportunities and challenges. We will show two examples from our own work where structural information on CYP2C9 and CYP3A4 inhibitor complexes have been successfully exploited in ongoing drug discovery projects.
Collapse
Affiliation(s)
- Gisela Brändén
- Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg S-405 30, Sweden.
| | - Tove Sjögren
- Discovery Sciences, AstraZeneca R&D Mölndal, Mölndal S-431 83, Sweden
| | - Volker Schnecke
- CVMD iMed, AstraZeneca R&D Mölndal, Mölndal S-431 83, Sweden
| | - Yafeng Xue
- Discovery Sciences, AstraZeneca R&D Mölndal, Mölndal S-431 83, Sweden
| |
Collapse
|
10
|
Tian C, Zhu L, Yu D, Cao Z, Kang T, Zhu R. The Stereoselectivity of CYP2C19 on R- and S-isomers of Proton Pump Inhibitors. Chem Biol Drug Des 2014; 83:610-21. [DOI: 10.1111/cbdd.12274] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2013] [Revised: 12/03/2013] [Accepted: 12/12/2013] [Indexed: 12/19/2022]
Affiliation(s)
- Chuan Tian
- School of Life Sciences and Technology; Tongji University; Shanghai 200092 China
- School of Pharmacy; Liaoning University of Traditional Chinese Medicine; Dalian Liaoning 116600 China
| | - Lixin Zhu
- Digestive Diseases and Nutrition Center; Department of Pediatrics; The State University of New York at Buffalo; Buffalo NY 14226 USA
| | - Dan Yu
- School of Pharmacy; Liaoning University of Traditional Chinese Medicine; Dalian Liaoning 116600 China
| | - Zhiwei Cao
- School of Life Sciences and Technology; Tongji University; Shanghai 200092 China
| | - Tingguo Kang
- School of Pharmacy; Liaoning University of Traditional Chinese Medicine; Dalian Liaoning 116600 China
| | - Ruixin Zhu
- School of Life Sciences and Technology; Tongji University; Shanghai 200092 China
- School of Pharmacy; Liaoning University of Traditional Chinese Medicine; Dalian Liaoning 116600 China
| |
Collapse
|
11
|
Moroy G, Martiny VY, Vayer P, Villoutreix BO, Miteva MA. Toward in silico structure-based ADMET prediction in drug discovery. Drug Discov Today 2011; 17:44-55. [PMID: 22056716 DOI: 10.1016/j.drudis.2011.10.023] [Citation(s) in RCA: 170] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2011] [Revised: 10/07/2011] [Accepted: 10/21/2011] [Indexed: 12/12/2022]
Abstract
Quantitative structure-activity relationship (QSAR) methods and related approaches have been used to investigate the molecular features that influence the absorption, distribution, metabolism, excretion and toxicity (ADMET) of drugs. As the three-dimensional structures of several major ADMET proteins become available, structure-based (docking-scoring) computations can be carried out to complement or to go beyond QSAR studies. Applying docking-scoring methods to ADMET proteins is a challenging process because they usually have a large and flexible binding cavity; however, promising results relating to metabolizing enzymes have been reported. After reviewing current trends in the field we applied structure-based methods in the context of receptor flexibility in a case study involving the phase II metabolizing sulfotransferases. Overall, the explored concepts and results suggested that structure-based ADMET profiling will probably join the mainstream during the coming years.
Collapse
Affiliation(s)
- Gautier Moroy
- Inserm UMR-S 973, Molécules Thérapeutiques In Silico, Université Paris Diderot, Sorbonne Paris Cité, 35 Rue Helene Brion, 75013 Paris, France
| | | | | | | | | |
Collapse
|